Literature DB >> 18823889

Predictive value of coronary artery stenoses and C-reactive protein levels in patients with stable coronary artery disease.

Ramón Arroyo-Espliguero1, Pablo Avanzas, Juan Quiles, Juan Carlos Kaski.   

Abstract

INTRODUCTION AND AIMS: Coronary occlusions resulting in acute events often occur at the site of non-severe stenoses. We sought to assess the prognostic value of non-obstructive coronary stenoses and C-reactive protein (CRP) levels in patients with chronic stable angina (CSA).
METHODS: We studied 790 consecutive patients with CSA who underwent routine coronary arteriography. High sensitivity CRP and coronary angiograms were assessed at study entry. Angiographic coronary disease severity was graded using a "vessel score" (number of coronary arteries showing at least 50% reduction in lumen diameter) and extent of disease with an "extension score" (proportion of the coronary artery tree showing angiographically detectable atheroma). Patients were followed up for 1 year.
RESULTS: Significant left main stem disease was present in 54 patients (6.8%). 368 patients (46.6%) underwent revascularization. 71 patients (9%) had at least one of the events comprised in the combined study end-point (unstable angina, myocardial infarction (AMI) and cardiac death). Patients who suffered cardiac adverse events had a significantly higher vessel score (n) (2.0 [2.0-3.0] vs. 2.0 [1.0-2.0], P<0.001), extension score (%) (23.5 [17-34.5] vs. 16.0 [6.0-27.0], P<0.001) and CRP levels (mg/L) (3.0 [1.8-7.2] vs. 2.3 [1.1-4.7], P=0.001) compared to patients without events. Age, previous history of AMI, vessel score, extension score and CRP levels were significantly associated with the study end-point. Multivariate analysis showed extension score (OR 5.3 [2.8-10.3] CI 95%; P<0.001), revascularization (OR 0.26 [0.14-0.48] CI 95%; P<0.001) and CRP levels (OR 1.9 [1.1-3.2] CI 95%; P=0.03), but not vessel score (P=0.1), to be independent predictors of the combined end-point.
CONCLUSIONS: In patients with CSA, independently of revascularization, extension score and CRP levels predict cardiac adverse events, regardless of the presence or absence of flow limiting coronary lesions.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18823889     DOI: 10.1016/j.atherosclerosis.2008.08.009

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  13 in total

Review 1.  Adipose tissue and vascular inflammation in coronary artery disease.

Authors:  Enrica Golia; Giuseppe Limongelli; Francesco Natale; Fabio Fimiani; Valeria Maddaloni; Pina Elvira Russo; Lucia Riegler; Renatomaria Bianchi; Mario Crisci; Gaetano Di Palma; Paolo Golino; Maria Giovanna Russo; Raffaele Calabrò; Paolo Calabrò
Journal:  World J Cardiol       Date:  2014-07-26

2.  Plasma CXCL1 levels and TRAF3IP2 variants in patients with myocardial infarction.

Authors:  Safoora Pordel; Mahdi Sajedi Khanian; Mohammad Hossein Karimi; Hossein Nikoo; Mehrnoosh Doroudchi
Journal:  J Clin Lab Anal       Date:  2018-02-12       Impact factor: 2.352

3.  Variation in high-sensitivity C-reactive protein levels over 24 hours in patients with stable coronary artery disease.

Authors:  Mevlut Koc; Osman Karaarslan; Gulcan Abali; Mustafa Kemal Batur
Journal:  Tex Heart Inst J       Date:  2010

Review 4.  CRP and the risk of atherosclerotic events.

Authors:  Paolo Calabrò; Enrica Golia; Edward T H Yeh
Journal:  Semin Immunopathol       Date:  2009-05-05       Impact factor: 9.623

Review 5.  Serum biomarkers for the detection of cardiac toxicity after chemotherapy and radiation therapy in breast cancer patients.

Authors:  Sibo Tian; Kim M Hirshfield; Salma K Jabbour; Deborah Toppmeyer; Bruce G Haffty; Atif J Khan; Sharad Goyal
Journal:  Front Oncol       Date:  2014-10-09       Impact factor: 6.244

Review 6.  Assessing Risk in Patients with Stable Coronary Disease: When Should We Intensify Care and Follow-Up? Results from a Meta-Analysis of Observational Studies of the COURAGE and FAME Era.

Authors:  Umberto Barbero; Fabrizio D'Ascenzo; Freek Nijhoff; Claudio Moretti; Giuseppe Biondi-Zoccai; Marco Mennuni; Davide Capodanno; Marco Lococo; Michael J Lipinski; Fiorenzo Gaita
Journal:  Scientifica (Cairo)       Date:  2016-04-27

Review 7.  The Role of C-reactive Protein in Patient Risk Stratification and Treatment.

Authors:  Ramón Arroyo-Espliguero; María C Viana-Llamas; Alberto Silva-Obregón; Pablo Avanzas
Journal:  Eur Cardiol       Date:  2021-07-07

8.  Atorvastatin reduces serum HMGB1 levels in patients with hyperlipidemia.

Authors:  Daoqun Jin; Yongbo Wu; Lin Zhao; Jie Guo; Kai Zhang; Zhiqiang Chen
Journal:  Exp Ther Med       Date:  2012-10-01       Impact factor: 2.447

9.  Severe multivessel coronary artery disease and high-sensitive troponin T.

Authors:  Inga Magdalena Huziuk; Małgorzata Lelonek
Journal:  Kardiochir Torakochirurgia Pol       Date:  2015-06-30

10.  Relationship of high sensitivity C-reactive protein with presence and severity of coronary artery disease.

Authors:  Syed Shahid Habib; Abeer A Al Masri
Journal:  Pak J Med Sci       Date:  2013-11       Impact factor: 1.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.